- The stock price of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) increased over 12% pre-market. This is why it happened.
The stock price of Bellicum Pharmaceuticals, Inc. (NASDAQ: BLCM) – a leader in developing novel, controllable cellular immunotherapies for cancers, and The University of Texas MD Anderson Cancer Center – increased over 12% pre-market. Investors are responding positively to Bellicum Pharmaceuticals announcing a global option and license agreement covering certain intellectual property and technology rights regarding Bellicum’s CaspaCIDe (inducible caspase-9, or iC9) safety switch and related technologies, and the use of rimiducid, an agent used to activate the safety switch. Through this agreement, MD Anderson will have the option to incorporate CaspaCIDe into certain cellular therapy programs.
Bellicum’s CaspaCIDe safety switch could facilitate the use of cell therapies where cytokine release syndrome and neurotoxicities have been observed in pursuit of novel targets with on-target/off-tumor safety concerns, and in conjunction with next-generation higher potency cell therapy constructs.
Upon the exercise of each option – typically expected to be upon out-license of an MD Anderson program that incorporates iC9 – Bellicum is going receive an upfront payment and will be entitled to a percentage of certain consideration paid to MD Anderson by the third party. And Bellicum also will receive a single-digit-percent royalty on global sales of the product.
Bellicum and MD Anderson agreed on the first 2 programs for development concurrent with the execution of the agreement. And this agreement expands upon a previous one, which covers the use of CaspaCIDe in a specific MD Anderson cell therapy program.
“We are excited to expand our CaspaCIDe agreement with MD Anderson to include a broader set of programs to benefit cancer patients. We believe that our switch technology may enhance the benefit/risk profile of cell therapies. We intend to continue to pursue opportunities to expand its use via external collaborations with other leaders in the field.”
— Rick Fair, President and CEO of Bellicum Pharmaceuticals
“The unique inducible caspase-9 technology covered by this agreement has the potential to reduce the risk of serious adverse events associated with cellular therapies and to improve patient outcomes. We have successfully applied the technology to existing cell therapies, and we look forward to the potential future applications made possible by this agreement.”
— Katy Rezvani, M.D., Ph.D., professor of Stem Cell Transplantation and Cellular Therapy at MD Anderson
Disclaimer: This content is intended for informational purposes. Before making any investment, you should do your own analysis.